Clinical Trial Update: Efficacy Study of Human Cytomegalovirus (HCMV) Hyperimmune Globulin to Prevent Congenital HCMV Infection [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 efficacy study of human cytomegalovirus hyperimmune globulin to prevent congenital cytomegalovirus infection has completed its evaluation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Cytomegalovirus Infection
• Cytomegalovirus Infection

Drugs mentioned

• Cytomegalovirus Hyperimmune Globulin (cytomegalovirus hyperimmune globulin)

Snippet

Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia | Conditions: Cytomegalovirus Infection | Phase 2, Phase 3 | Status: COMPLETED